Krystal Biotech, Inc. $KRYS Shares Sold by Lisanti Capital Growth LLC

Lisanti Capital Growth LLC cut its holdings in shares of Krystal Biotech, Inc. (NASDAQ:KRYS) by 44.8% during the third quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 10,525 shares of the company’s stock after selling 8,525 shares during the period. Lisanti Capital Growth LLC’s holdings in Krystal Biotech were worth $3,500,000 as of its most recent SEC filing.

Other institutional investors have also recently modified their holdings of the company. Hsbc Holdings PLC acquired a new position in shares of Krystal Biotech during the 2nd quarter worth approximately $3,653,000. VIRGINIA RETIREMENT SYSTEMS ET Al purchased a new position in shares of Krystal Biotech during the 2nd quarter valued at approximately $3,865,000. Congress Asset Management Co. lifted its position in shares of Krystal Biotech by 34.8% during the 3rd quarter. Congress Asset Management Co. now owns 54,083 shares of the company’s stock valued at $17,986,000 after buying an additional 13,949 shares in the last quarter. Corient Private Wealth LP grew its stake in Krystal Biotech by 767.4% in the 2nd quarter. Corient Private Wealth LP now owns 30,558 shares of the company’s stock valued at $11,357,000 after acquiring an additional 27,035 shares during the period. Finally, Bank of America Corp DE grew its stake in Krystal Biotech by 36.6% in the 1st quarter. Bank of America Corp DE now owns 260,647 shares of the company’s stock valued at $67,330,000 after acquiring an additional 69,840 shares during the period. 86.29% of the stock is currently owned by institutional investors and hedge funds.

Krystal Biotech Stock Performance

Shares of KRYS opened at $308.81 on Thursday. Krystal Biotech, Inc. has a one year low of $198.02 and a one year high of $382.54. The stock has a market capitalization of $9.15 billion, a price-to-earnings ratio of 41.59 and a beta of 0.56. The stock has a 50 day moving average price of $329.35 and a 200 day moving average price of $309.43.

Krystal Biotech (NASDAQ:KRYS) last announced its quarterly earnings data on Monday, November 2nd. The company reported $2.05 earnings per share for the quarter, beating analysts’ consensus estimates of $1.79 by $0.26. Krystal Biotech had a return on equity of 17.02% and a net margin of 47.91%. The company had revenue of $127.34 million for the quarter, compared to analyst estimates of $125.77 million. On average, analysts predict that Krystal Biotech, Inc. will post 7.74 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several equities research analysts recently commented on the stock. Bank of America boosted their price target on shares of Krystal Biotech from $392.00 to $400.00 and gave the stock a “buy” rating in a report on Monday, September 21st. William Blair raised shares of Krystal Biotech to a “strong-buy” rating in a report on Wednesday, September 23rd. Weiss Ratings downgraded shares of Krystal Biotech from a “buy (b)” rating to a “buy (b-)” rating in a report on Wednesday, November 4th. Citigroup dropped their target price on shares of Krystal Biotech from $416.00 to $412.00 and set a “buy” rating on the stock in a research report on Tuesday, November 3rd. Finally, Zacks Research cut shares of Krystal Biotech from a “hold” rating to a “strong sell” rating in a research note on Friday, October 23rd. Two investment analysts have rated the stock with a Strong Buy rating, ten have assigned a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $375.00.

Insider Transactions at Krystal Biotech

In other Krystal Biotech news, Director Dino Rossi sold 25,000 shares of the stock in a transaction dated Friday, August 14th. The shares were sold at an average price of $329.12, for a total value of $8,228,000.00. Following the completion of the sale, the director owned 50,000 shares in the company, valued at approximately $16,456,000. This represents a 33.33% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Suma Krishnan sold 25,000 shares of the firm’s stock in a transaction that occurred on Friday, September 4th. The stock was sold at an average price of $359.32, for a total transaction of $8,983,000.00. Following the completion of the transaction, the insider directly owned 1,302,145 shares in the company, valued at $467,886,741.40. This trade represents a 1.88% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 13.10% of the stock is currently owned by corporate insiders.

Krystal Biotech Profile

Krystal Biotech, Inc. is a biotechnology company that develops genetic medicines for people with serious diseases. Founded in 2016 and headquartered in Pittsburgh, Pennsylvania, the company focuses on treatments that deliver functional genes to patients’ cells. Its commercial product, Vyjuvek (beremagene geperpavec-svdt), is a topical gene therapy for wounds associated with dystrophic epidermolysis bullosa, a rare inherited skin disorder. The treatment is designed to help cells produce collagen VII, a protein that supports the skin’s structure.